复星医药：关于控股子公司药品注册申请进展的公告

Core Viewpoint - Fosun Pharma's subsidiary, Fosun Wanguo (Jiangsu) Pharmaceutical Group, has received notification from the National Medical Products Administration regarding the withdrawal of its registration application for Dihydroartemisinin-Ruxolitinib capsules [2] Group 1 - The announcement was made on the evening of October 14 [2] - The withdrawal of the registration application indicates a strategic decision by the company [2]